Pharmafile Logo
Pharmafocus logo
Advanced Search

Cabometyx

Showing 7 posts of 7 posts found.

Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy

November 30, 2020
Sales and Marketing Cabometyx, Japan, Takeda

The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …

News
ipsen-logo-big

Ipsen’s Cabometyx gains European approval in hepatocellular carcinoma

November 16, 2018
Medical Communications, Sales and Marketing Cabometyx, carcinoma, ipsen, pharma. European Commission

Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular …

News
shutterstock_gonnorrhea

Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer

July 5, 2018
Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma

French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …

News

Ipsen receives European first-line approval for Cabometyx

May 17, 2018
Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …

News
cabometyx_tablets_60_mg_40_mg_20_mg

Ipsen ends P3 trial on liver cancer early due to strong data

January 18, 2018
Research and Development Cabometyx, Exelixis, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …

News

Ipsen secures NICE approval for multi-targeting kidney cancer therapy

July 11, 2017
Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE

Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …

News
exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024